A new trading day began on Friday, with C4 Therapeutics Inc (NASDAQ: CCCC) stock price down -2.75% from the previous day of trading, before settling in for the closing price of $6.91. CCCC’s price has ranged from $1.06 to $11.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 7.65% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 30.76%. With a float of $57.71 million, this company’s outstanding shares have now reached $60.47 million.
In an organization with 145 employees, it is important to assess its efficiency.
C4 Therapeutics Inc (CCCC) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 15.88%, while institutional ownership is 71.91%.
C4 Therapeutics Inc (CCCC) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 6.72 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -36.05% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Here are C4 Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.88 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Let’s dig in a bit further. During the last 5-days, its volume was 1.45 million. That was inferior than the volume of 3.73 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 16.41%. Additionally, its Average True Range was 0.54.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 52.31%, which indicates a significant increase from 12.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.71% in the past 14 days, which was lower than the 200.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.48, while its 200-day Moving Average is $4.57. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $7.07. Second resistance stands at $7.43. The third major resistance level sits at $7.70. If the price goes on to break the first support level at $6.45, it is likely to go to the next support level at $6.18. Assuming the price breaks the second support level, the third support level stands at $5.82.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
With a market capitalization of 460.99 million, the company has a total of 68,601K Shares Outstanding. Currently, annual sales are 20,760 K while annual income is -132,490 K. The company’s previous quarter sales were 3,260 K while its latest quarter income was -34,750 K.
